Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study

Casey M. Rebholz1, Brad C. Astor2, Morgan E. Grams1,3, Marc K. Halushka4, Mariana Lazo1,5, Ron C. Hoogeveen6, Christie M. Ballantyne6, Josef Coresh1,5 and Elizabeth Selvin1,5

1Department of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2Departments of Medicine and Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, 3Division of Nephrology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA, 4Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA, 5Division of General Internal Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA and 6Department of Medicine, Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, Houston, TX, USA

Correspondence and offprint requests to: Casey M. Rebholz; E-mail: crebholl1@jhu.edu

ABSTRACT

Background. Advanced glycation end products and their cell-bound receptors are thought to mediate the adverse effects of vascular disease through oxidative stress, inflammation and endothelial dysfunction. We examined the association between the soluble form of receptor for advanced glycation end products (sRAGE) and kidney disease.

Methods. In this case-cohort study nested within the Atherosclerosis Risk in Communities (ARIC) study, baseline sRAGE

20. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. JASA 1989; 84: 1074–1078

Received for publication: 14.11.2013; Accepted in revised form: 25.6.2014
levels were measured in a cohort random sample of participants without kidney disease (n = 1218), and among participants who developed incident chronic kidney disease (CKD) [estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m² and ≥25% eGFR decline, n = 151] and end-stage renal disease (ESRD) [entry in the US Renal Data System (USRDS) registry, n = 152].

**Results.** Baseline sRAGE levels were inversely related to baseline eGFR (r = −0.13). After adjusting for age, sex and race, one interquartile range higher log_{10}-transformed sRAGE was associated with development of CKD [odds ratio: 1.39; 95% confidence interval (95% CI) 1.06–1.83; P = 0.02] and ESRD (hazard ratio: 1.97; 95% CI 1.47–2.64; P < 0.001). These associations were not significant after eGFR adjustment.

**Conclusions.** High sRAGE levels are associated with incident CKD and ESRD risk, but not after adjustment for kidney function at baseline. Future studies are needed to investigate specific mechanisms underlying the association of sRAGE with kidney disease risk.

**Keywords:** advanced glycation end product receptor, chronic kidney failure, risk factors

---

**INTRODUCTION**

Advanced glycation end products (AGEs), which are produced by the Maillard reaction and their cell-bound receptors (RAGE) are thought to mediate the adverse effects of dysglycemia and vascular disease [1–4]. Activation of the AGE–RAGE complex contributes to reactive oxygen species generation, inflammation and endothelial dysfunction, thereby contributing to chronic disease progression [5–7]. The soluble form of RAGE (sRAGE) is a 48-kDa, positively charged cleavage product of RAGE, which retains the ligand binding site but lacks the transmembrane and signaling domains [8, 9]. sRAGE has gained attention due to its ability to bind the various ligands of RAGE, including high mobility group box 1, S100/calgranulin and β-amyloid protein in addition to AGEs [10]. By binding to AGEs and other ligands without initiating the signaling cascade, sRAGE is thought to neutralize the detrimental effects of AGE–RAGE complex activation [10, 11]. Due to this purported protective role, sRAGE has even been proposed as a therapeutic agent targeting vascular inflammation for the prevention of cardiovascular disease [11, 12].

Whereas there is growing literature on sRAGE and its associations with diabetes and cardiovascular disease, the role of this marker in the development of kidney disease is not well characterized. Prior studies show that sRAGE levels are elevated among patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) relative to individuals without kidney disease or with less severe disease [13–16]. These studies also report that sRAGE levels are inversely correlated with kidney function in cross-sectional analyses [13, 14, 16]. In an analysis of 230 older women, a higher sRAGE level at baseline was associated with a greater likelihood of developing CKD after 12 months [n = 32 incident CKD cases; odds ratio (OR): 1.32; 95% confidence interval (95% CI) 1.01–1.74; P = 0.05] [16]. Additional studies with longer follow-up, larger sample sizes, and with adjustment for estimated glomerular filtration rate (eGFR) are needed to confirm this isolated finding.

We hypothesized that higher plasma concentrations of sRAGE at baseline would be accompanied by decreased kidney function and associated with increased risk of incident CKD and ESRD in a community-based population.

**MATERIALS AND METHODS**

**Study design**

The Atherosclerosis Risk in Communities (ARIC) study is a community-based cohort study of 15 792 individuals recruited from four US communities (Washington County, MD; Forsyth County, NC; Jackson, MS; Minneapolis, MN), which has been previously described [17]. Briefly, ARIC study participants were initially enrolled in 1988–89 and additionally examined at follow-up study visits (1990–92, 1993–95, 1996–98, 2011–13) to collect information on demographics, health history, lifestyle characteristics, anthropometrics and biological specimens (12-h fasting blood samples, spot urine samples). Blood samples were centrifuged within 30 min of venipuncture and stored at −70°C until analysis. We report here the results of a nested case-cohort study within the ARIC study.

**Nested case-cohort study population**

To be eligible for the case-cohort study, all participants were required to have attended the baseline visit (ARIC study visit 2, 1990–92; n = 14 348, 90.9% of the ARIC cohort), a measured serum creatinine value (n = 14 292, 99.6% of participants who attended the baseline visit) and normal kidney function at baseline, defined as eGFR ≥60 ml/min/1.73 m² (n = 13 983, 97.8% of those with measured serum creatinine). Of these participants, we selected a random sample of the cohort to serve as the comparison group (cohort random sample: n = 1218) and all incident cases of CKD and ESRD for measurement of sRAGE in plasma samples collected at baseline. The primary case group was all participants who developed CKD (n = 151). The secondary case group consisted of all participants who developed ESRD (renal replacement therapy; n = 152).

**Definition of incident chronic kidney disease**

CKD status was defined as eGFR <60 ml/min/1.73 m² and ≥25% decline in eGFR at follow-up (ARIC study visit 4, 1996–98) relative to baseline. The incident CKD case group consisted of 151 participants, including 21 participants selected for the cohort random sample (cases: n = 151; noncases: n = 1197; total sample: N = 1348).

**Definition of incident end-stage renal disease**

Incident ESRD cases (renal replacement therapy) were identified through the US Renal Disease System (USRDS)
registry by entry date between baseline and 31 December 2005. This registry captures patients receiving dialysis or transplant as reported on the Centers for Medicare and Medicaid Services Medical Evidence Form-2728, which is filed within 45 days of renal replacement therapy initiation. There were 152 ESRD cases including five cases that overlapped with the cohort random sample (cases: \( n = 152 \); noncases: \( n = 1213 \); total sample: \( N = 1365 \)). In a sensitivity analysis, we used an alternative outcome definition incorporating untreated as well as treated kidney failure and results were similar to that for ESRD defined by entry into the USRDS registry.

**Measurement of sRAGE**

Baseline plasma levels of sRAGE were measured with a commercially-available ELISA kit (Quantikine® Human RAGE Immunoassay, R&D Systems, Minneapolis, MN). The intra- and interassay coefficients of variation for the assay were 2.8 and 9.6%, respectively. The sRAGE assay has been shown to be robust to numerous adverse pre-analytical conditions including multiple freeze-thaw cycles and delayed centrifugation [18, 19]. Study and laboratory staff were blinded to kidney disease case status for measurement of sRAGE and other covariates.

**Measurement of covariates**

Creatinine was measured by the modified kinetic Jaffé method and calibrated to the National Institute of Standards and Technology standard [20]. Serum cystatin C was measured using a particle-enhanced turbidimetric assay (Gentian, Moss, Norway). eGFR was calculated with CKD Epidemiology Collaboration equations using creatinine only (eGFRCr), cystatin C only (eGFRCys) and both creatinine and cystatin C (eGFRCr-Cys) [21, 22]. Serum levels of \( \beta_2 \) microglobulin and \( \beta \)-trace protein were measured using particle-enhanced immune-nephelometric N Latex assays (Siemens Diagnostics, IL). C-reactive protein was measured from stored plasma samples using a latex-particle-enhanced immunoturbidimetric assay on the Roche Modular P800 Chemistry analyzer (Roche Diagnostics, Indianapolis, IN). Hemoglobin A1c was measured from stored whole blood samples using high-performance liquid chromatography, and standardized to the Diabetes Control and Complications Trial hemoglobin A1c assay [23]. Plasma high-density lipoprotein cholesterol levels were measured enzymatically after precipitation with dextran sulfate-magnesium [24]. Three seated measurements of blood pressure were taken by a certified technician using a random-zero sphygmomanometer after 5 min of rest, and the mean of the second and third readings was used for analysis. Body mass index was calculated as weight (kg)/height (m)² using measurements taken during the study clinical examination. Participants reported their date of birth, sex, race, current smoking status and physician-diagnosed diabetes and use of hypoglycemic medication or insulin through a structured interview with a trained interviewer.

**Statistical analysis**

sRAGE quartiles were created based on the distribution of sRAGE in the cohort random sample and, for continuous analyses, sRAGE was log10-transformed to improve normality of its distribution. Descriptive statistics were used to describe the study population overall and to examine differences by sRAGE quartile. Differences in baseline characteristics by sRAGE quartile were tested using analysis of variance and \( \chi^2 \) tests. Pairwise Spearman rank correlation coefficients were calculated in the cohort random sample for sRAGE and other clinical analytes.

Logistic regression models were used to examine the association between sRAGE and incident CKD, since CKD status was assessed at a discrete time point (ARIC study visit 4, 1996–98). Cox proportional hazard regression models were used to examine the association between sRAGE and incident ESRD, incorporating time from baseline (1990–92) until the date of entry into the USRDS ESRD registry or censoring due to death or end of follow-up (31 December 2005). Risk ratios were estimated per one interquartile range increase of log10-transformed sRAGE, which was calculated based on the sRAGE distribution in the cohort random sample. Inverse probability weighting was used to account for random selection of participants from the overall ARIC cohort for the sub-cohort [25, 26]. Competing risks regression models were used to examine the association between sRAGE and kidney disease, accounting for deaths that occurred before kidney events.

To examine the independent association of sRAGE with incident CKD and ESRD, we compared several multivariable models adjusted for baseline covariates. Model 1 included basic demographic characteristics (age, sex, and race). Model 2 included all variables in Model 1 plus eGFRCr-Cys, because this estimate is our best approximation of measured GFR [21]. As a sensitivity analysis, we substituted eGFRCr and eGFRCys for eGFRCr-Cys in separate models, and results were similar. Model 3 included all variables in Model 2 plus additional markers of kidney filtration (\( \beta_2 \) microglobulin, \( \beta \)-trace protein), diabetes status due to the known association of diabetes with both sRAGE and kidney disease, and traditional kidney disease risk factors (high-density lipoprotein, body mass index, systolic blood pressure, current smoking status, C-reactive protein). We conducted analyses stratified by racial group, diabetes status, sex and by angiotensin-converting enzyme (ACE) inhibitor use based on knowledge from previous studies. Restricted cubic splines were used to present age, sex and race-adjusted as well as age, sex, race and eGFR-adjusted hazard ratios for ESRD by continuous sRAGE level with knots at 439.6, 733.7, 965.6, 1244.5 and 2034.6 pg/mL, centering at the 25th percentile, and truncation of sRAGE values at the 1st and 99th percentiles. Statistical tests were two-sided, significance was assessed at an \( \alpha \) level of 0.05, and analyses were performed using Stata version 12.1 statistical software (StataCorp, LLC, College Station, TX).

**RESULTS**

Among noncases, 58.1% were women, 21.5% were black and baseline eGFR was 97.2 mL/min/1.73 m² (Supplementary data, Table S1). Relative to noncases, participants in the CKD
and ESRD case groups were more likely to be older, male, black, cigarette smokers, to have diabetes and higher systolic blood pressure levels. At the higher quartiles of plasma concentration of sRAGE, there were more women, fewer blacks and lower levels of hemoglobin A1c, systolic blood pressure, body mass index and C-reactive protein (Table 1). Among participants with sRAGE levels in the higher quartiles, eGFR was lower and kidney filtration markers were higher. Baseline sRAGE levels were inversely related to baseline eGFR ($r = -0.13$, $P < 0.001$) and positively correlated with kidney filtration markers ($\beta_2$ microglobulin: $r = -0.09$, $P = 0.001$; $\beta$-trace protein: $r = -0.17$, $P < 0.001$).

After adjusting for age, sex and race, higher baseline concentration of sRAGE was statistically significantly associated with an increased risk of kidney disease [Table 2; CKD OR: 1.39, 95% CI 1.06–1.83, $P = 0.02$; ESRD hazard ratio (HR): 1.97, 95% CI 1.47–2.64, $P < 0.001$]. Effect estimates were substantially attenuated after accounting for eGFR (CKD OR: 1.22, 95% CI 0.92–1.62, $P = 0.16$; ESRD HR: 1.08, 95% CI 0.87–1.34, $P = 0.49$). In the fully adjusted model, plasma levels of sRAGE were significantly associated with CKD (OR: 1.37; 95% CI 1.01–1.87; $P = 0.04$), but not ESRD (HR: 1.01; 95% CI 0.74–1.37; $P = 0.9$). Accounting for the competing risk of death prior to a kidney disease event resulted in quantitative results and interpretation similar to that from the standard survival analysis.

With higher levels of sRAGE, the age-, sex- and race-adjusted risk of ESRD increased approximately linearly (Figure 1A). Additional adjustment for eGFR resulted in a nearly flat line, representing no association between sRAGE and ESRD (Figure 1B).

sRAGE was not significantly associated with kidney disease outcomes among persons with diabetes, whereas there were statistically significant positive associations between sRAGE and kidney disease outcomes among participants without diabetes in some models (Supplementary data, Table S2). The diabetes–sRAGE interaction term was statistically significant in fully adjusted models for ESRD, but not CKD (Supplementary data, Table S2; Model 2 and Model 3).

### Table 1. Baseline demographics, clinical characteristics and measures of kidney function by quartile of soluble receptor for advanced glycation end products (sRAGE) in the cohort random sample (N = 1218)\(^a\)

<table>
<thead>
<tr>
<th>sRAGE, pg/mL</th>
<th>Quartile 1: 119.4–708.8 (n = 305)</th>
<th>Quartile 2: 708.9–965.2 (n = 305)</th>
<th>Quartile 3: 965.3–1262.6 (n = 304)</th>
<th>Quartile 4: 1262.7–4650.4 (n = 304)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>56.6 (5.8)</td>
<td>56.6 (5.5)</td>
<td>56.7 (5.8)</td>
<td>56.5 (5.5)</td>
</tr>
<tr>
<td>Female</td>
<td>51.5% (157)</td>
<td>56.1% (171)</td>
<td>55.9% (170)</td>
<td>68.4% (208)</td>
</tr>
<tr>
<td>Black</td>
<td>45.3% (138)</td>
<td>22.0% (67)</td>
<td>12.2% (37)</td>
<td>6.6% (20)</td>
</tr>
<tr>
<td>Diagnosed diabetes</td>
<td>5.9% (18)</td>
<td>6.9% (21)</td>
<td>5.9% (18)</td>
<td>3.3% (10)</td>
</tr>
<tr>
<td>Hemoglobin A1c, %</td>
<td>5.9 (1.1)</td>
<td>5.7 (1.2)</td>
<td>5.6 (0.9)</td>
<td>5.5 (0.8)</td>
</tr>
<tr>
<td>Hemoglobin A1c, mmol/mol</td>
<td>41 (12.0)</td>
<td>39 (13.1)</td>
<td>38 (9.8)</td>
<td>37 (8.7)</td>
</tr>
<tr>
<td>Systolic blood pressure, mmHg</td>
<td>124.6 (17.0)</td>
<td>120.9 (16.3)</td>
<td>119.2 (18.2)</td>
<td>116.7 (18.7)</td>
</tr>
<tr>
<td>ACE inhibitor medication use</td>
<td>6.9% (21)</td>
<td>6.9% (21)</td>
<td>6.3% (19)</td>
<td>3.3% (10)</td>
</tr>
<tr>
<td>History of coronary heart disease</td>
<td>8.0% (24)</td>
<td>4.7% (14)</td>
<td>9.4% (28)</td>
<td>2.3% (7)</td>
</tr>
<tr>
<td>Current smoker</td>
<td>15.4% (47)</td>
<td>21.3% (65)</td>
<td>20.4% (62)</td>
<td>16.1% (49)</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>30.2 (5.7)</td>
<td>28.0 (5.2)</td>
<td>27.5 (5.0)</td>
<td>25.8 (4.3)</td>
</tr>
<tr>
<td>High-density lipoprotein, mg/dL(^a)</td>
<td>49.8 (16.2)</td>
<td>49.4 (14.6)</td>
<td>49.1 (16.5)</td>
<td>52.8 (16.3)</td>
</tr>
<tr>
<td>C-reactive protein, mg/L</td>
<td>5.68 (7.5)</td>
<td>3.65 (5.6)</td>
<td>3.51 (5.8)</td>
<td>2.97 (4.5)</td>
</tr>
<tr>
<td>$\beta_2$ Microglobulin, mg/L</td>
<td>1.83 (0.39)</td>
<td>1.85 (0.34)</td>
<td>1.87 (0.35)</td>
<td>1.91 (0.35)</td>
</tr>
<tr>
<td>$\beta$-trace protein, mg/L</td>
<td>0.49 (0.17)</td>
<td>0.55 (0.34)</td>
<td>0.58 (0.15)</td>
<td>0.60 (0.16)</td>
</tr>
<tr>
<td>Cystatin C, mg/L</td>
<td>0.84 (0.14)</td>
<td>0.85 (0.14)</td>
<td>0.86 (0.15)</td>
<td>0.87 (0.15)</td>
</tr>
<tr>
<td>eGFR, mL/min/1.73 m²</td>
<td>99.9 (15.0)</td>
<td>96.8 (13.0)</td>
<td>96.1 (14.1)</td>
<td>95.0 (12.8)</td>
</tr>
</tbody>
</table>

\(^a\)Mean (standard deviation) or % (n).

\(^b\)Analysis of variance for continuous variables, $\chi^2$ for categorical variables.

\(^c\)To convert high-density lipoprotein from mg/dL to mmol/L, multiply by 0.02586.

\(^d\)Model 1: Age, sex, race.

\(^e\)Model 2: Variables in Model 1 + baseline estimated glomerular filtration rate.

\(^f\)Model 3: Variables in Model 2 + $\beta_2$ microglobulin, $\beta$-trace protein, diabetes, high-density lipoprotein, body mass index, systolic blood pressure, current smoking status, C-reactive protein.
Plasma levels of sRAGE were not different among participants using ACE inhibitors compared with participants not taking this class of medication (Table 1; ACE inhibitor users: mean sRAGE = 1067.9 pg/mL; ACE inhibitors nonusers: mean sRAGE = 1057.9 pg/mL; P = 0.42). In stratified analyses, the association of sRAGE and kidney outcomes did not differ by use of ACE inhibitors.

There were substantial differences in sRAGE levels by race, as 45.3% of those within the lowest sRAGE quartile were black and only 6.6% of those in the highest sRAGE quartile were black (Table 1; P < 0.001). There were no significant differences in the association of sRAGE and kidney disease outcomes by race (CKD: P for interaction = 0.81; ESRD: P for interaction = 0.29) or sex (CKD: P for interaction = 0.40; ESRD: P for interaction = 0.22).

**DISCUSSION**

In this biracial, community-based study of middle-aged adults, higher plasma concentrations of sRAGE at baseline were associated with concurrent indicators of worse kidney function as well as increased risk of incident kidney disease during follow-up, after accounting for age, sex and race. However, the association between sRAGE level and kidney disease was not independent of baseline kidney function assessed by eGFR, suggesting a possible direct effect of kidney filtration on circulating serum levels of sRAGE.

We report an increased risk of kidney disease associated with higher levels of sRAGE, which corroborates findings from prior studies focused on kidney disease as the primary outcome [13–16]. Expanding upon existing evidence and leveraging the strengths of the ARIC study, we conducted several subgroup analyses and controlled for numerous parameters known to be related to sRAGE and kidney disease. Importantly, our study is the first to adjust for eGFR in estimating the association between sRAGE and kidney disease. The inclusion of eGFR in multivariable regression models substantially attenuated the effect estimates. In addition, we observed that baseline sRAGE was cross-sectionally associated with worse kidney function, i.e. inversely correlated with eGFR and positively correlated with other kidney filtration markers (β2 microglobulin, β-trace protein). Taken together, these findings suggest that circulating levels of sRAGE may be directly affected by impairment of the kidney to filter endogenous substances appropriately or, conversely, that sRAGE directly impacts kidney function. In contrast with the current kidney disease literature reporting that higher sRAGE levels are associated with adverse outcomes, previous studies have demonstrated that lower levels of sRAGE are associated with increased risk of diabetes, cardiovascular disease and mortality [2, 27, 28]. However, there is some inconsistency in the directionality of the association with vascular disease which may be the result of effect modification by underlying disease status [29, 30].

Findings from stratified analyses in the current study add to the knowledge base on variability of the association between sRAGE and kidney disease within population subgroups. The sRAGE and kidney disease relationship was present among persons without diabetes but not among persons with diabetes in our study. The notable difference in sRAGE distribution by racial group in our study, with lower sRAGE concentrations among blacks, is in agreement with previous reports [2, 27, 28, 30]. In spite of the difference in sRAGE concentrations between racial groups, we found that the association between sRAGE and kidney outcomes was consistent across racial groups. Inhibition of renin–angiotensin system activity through the use of ACE inhibitors is thought to increase production and secretion of sRAGE in plasma [31]. We found that use of ACE inhibitors was more common among kidney disease cases than noncases. However, there was no difference in sRAGE level by ACE inhibitor use and ACE inhibitor use did not impact risk estimation in stratified analysis. Similarly, a cross-sectional study of individuals with ESRD found that sRAGE level was not associated with ACE inhibitor use [14]. However, use of ACE inhibitors in our study was reported at baseline (1990–92) and may not be reflective of current patterns of medication use. Furthermore, the small size of individual strata limits our ability to make definitive conclusions about results in small subgroups.
The mechanism through which sRAGE exerts its influence on tissues and signaling pathways is not fully elucidated. One possibility is that sRAGE levels may reflect the degree of AGE-RAGE activity, which may in turn contribute to adverse health consequences [1, 4, 5]. That is, in the presence of high levels of circulating AGEs, RAGE mRNA expression increases, resulting in upregulation of RAGE production [32]. Given that sRAGE can be a cleaved product of RAGE, the plasma concentration of sRAGE could correspond to the amount of RAGE produced. Another potential explanation is that, similar to AGEs, elevated levels of circulating sRAGE result from decreased renal clearance and subsequent accumulation of sRAGE among those with decreased kidney function [33, 34]. That is, plasma levels of sRAGE may be partially determined by the kidney’s ability to filter effectively. sRAGE concentration in the circulation may represent the inflammatory state, and thereby lead to kidney disease pathogenesis [5, 35].

The present study is the largest with the longest follow-up time to investigate sRAGE and kidney disease and our results were consistent across two kidney disease outcomes. This study benefitted from the rigorous measurement of known risk factors for kidney disease and the use of a diverse, community-based study population.

There are several limitations that are important in interpreting these results. Firstly, we only had single measurements of sRAGE obtained from samples in long-term storage. However, the reproducibility of sRAGE measurements in masked duplicate specimens was high ($r = 0.99$, $n = 20$), and stable over a 3-year interval within the same participants ($r = 0.78$, $n = 179$) [36]. Secondly, only sRAGE levels were captured. The additional assessment of AGE concentration in the circulation may provide a more complete depiction of the mechanism of sRAGE. Thirdly, GFR was not measured directly. However, our findings were robust across different assessments of eGFR, including eGFRCr-Cys, which most closely approximates measured GFR [21]. Analyses of population subgroups are limited by smaller sample sizes than the overall study population, and these findings should be validated in studies with sufficient statistical power to assess subgroup differences. There may be selection bias due to loss-to-follow-up in the analysis of incident CKD in which eligibility was determined by the kidney filter effectively. sRAGE concentration in the circulation may represent the in inflammatory state, and thereby lead to kidney disease pathogenesis [5, 35].

In conclusion, our study demonstrates that high levels of circulating sRAGE are associated with worse kidney function and are a risk marker for the development of both early and late stage kidney disease. Notably, the direction of the association of sRAGE and kidney disease is the inverse of that for other chronic diseases. Furthermore, the observed associations appeared to be largely explained by baseline kidney function suggesting a possible direct effect of kidney filtration on circulating plasma sRAGE levels.

**SUPPLEMENTARY DATA**

Supplementary data are available online at http://ndt.oxfordjournals.org.

**ACKNOWLEDGEMENTS**

The Atherosclerosis Risk in Communities study is carried out as a collaborative study supported by National Heart, Lung and Blood Institute contracts (HHSN26820110005C, HHSN 268201100006C, HHSN268201100007C, HHSN26820110008C, HHSN268201100009C, HHSN268201100010C, HHSN 268201100011C and HHSN268201100012C). The authors thank the staff and participants of the Atherosclerosis Risk in Communities study for their important contributions. This research was supported by the National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK076770 and also a grant from the American Heart Association to Dr Selvin. Dr Rebholz is supported in part by National Heart, Lung and Blood Institute grant T32HL007024. Some of the data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US government.

**CONFLICT OF INTEREST STATEMENT**

None declared.

**REFERENCES**


82 C.M. Rebholz et al.
15. Kim JK, Park S, Lee MJ et al. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (en-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis 2012; 220: 208–214

Received for publication: 2.7.2014; Accepted in revised form: 27.7.2014